Edwards Lifesciences Corporation ($EW) Stock Forecast: Up 5.1% Today

What is Edwards Lifesciences Corporation?

Edwards Lifesciences (NYSE: EW) is a medical device company recognized for its advancements in heart disease treatments, notably its Transcatheter Aortic Valve Replacement (TAVR) platform.

Why is Edwards Lifesciences Corporation going up?

EW stock is up 5.1% on Dec 4, 2024 17:42

• Today, the positive outlook outlined at an investor conference contributed to the bullish movement in Edwards Lifesciences' stock. The company is anticipated to experience growth in total sales and therapy segments.
• Despite dealing with investor class action lawsuits and alerts from various law firms, the market appears to be more interested in the company's growth potential and financial prospects.
• Investors are showing optimism towards the potential expansion in TAVR and TMTT sales, potentially overshadowing the legal hurdles currently faced by the company.
• The recent market trend indicates that investors are primarily influenced by Edwards Lifesciences' future growth opportunities rather than its ongoing legal challenges, resulting in an upward momentum in the stock price.

EW Price Chart

EW Technical Analysis

EW News

Edwards Lifesciences Outlines Vision For Growth At Investor Conference - Edwards Lifesciences ( NYSE:EW )

2025 Financial Outlook: $5.6-$6 billion in total sales; adjusted EPS of $2.40-$2.50. Therapy Growth: TAVR sales projected at $4.1-$4.4 billion ( 5%-7% growth ) ; TMTT sales expected to rise by 50%-60%. Benzinga shares with you top insiders news

https://www.benzinga.com/general/health-care/24/12/42320501/edwards-lifesciences-outlines-vision-for-growth-at-investor-conference

Edwards Lifesciences ( EW ) Faces Investor Class Action Lawsuit Over TAVM Platform Disclosures, Deadline Pending - Hagens Berman - Edwards Lifesciences ( NYSE:EW )

SAN FRANCISCO , Dec. 04, 2024 ( GLOBE NEWSWIRE ) -- Investors in Edwards Lifesciences Corporation EW contend that the medical device giant misled them about the growth prospects of its core product, the Transcatheter Aortic Valve Replacement ( TAVR ) platform.

https://www.benzinga.com/pressreleases/24/12/g42319879/edwards-lifesciences-ew-faces-investor-class-action-lawsuit-over-tavm-platform-disclosures-deadlin

Edwards Lifesciences Corporation Investors: Please contact the Portnoy Law Firm to recover your losses. December 13, 2024 Deadline to file Lead Plaintiff Motion. - Edwards Lifesciences ( NYSE:EW )

Investors can contact the law firm at no cost to learn more about recovering their losses

https://www.benzinga.com/pressreleases/24/12/g42278481/edwards-lifesciences-corporation-investors-please-contact-the-portnoy-law-firm-to-recover-your-los

EDWARDS LIFESCIENCES CORPORATION ( NYSE: EW ) INVESTOR ALERT: Bernstein Liebhard LLP Reminds Edwards Lifesciences Corporation Investors of Upcoming Deadline - Edwards Lifesciences ( NYSE:EW )

NEW YORK, Dec. 02, 2024 ( GLOBE NEWSWIRE ) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Edwards Lifesciences Corporation EW? Did you purchase your shares between February 6, 2024 and July 24, 2024, inclusive? Did you lose money in your investment in Edwards Lifesciences ...

https://www.benzinga.com/pressreleases/24/12/g42271841/edwards-lifesciences-corporation-nyse-ew-investor-alert-bernstein-liebhard-llp-reminds-edwards-lif

EW INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Edwards Lifesciences ( NYSE:EW )

NEW YORK, Dec. 01, 2024 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Edwards Lifesciences Corporation ( "Edwards" or "the Company" ) EW and certain of its ...

https://www.benzinga.com/pressreleases/24/12/g42257587/ew-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-edwards-lifesciences-corporation-i

Trending Today

Bonk ($BONK) Crypto Forecast: Up 5.1% Today

Optimism ($OP) Crypto Forecast: Up 5.0% Today

Stellar ($XLM) Crypto Forecast: Up 5.1% Today

Pepe ($PEPE) Crypto Forecast: Up 5.0% Today

XRP ($XRP) Crypto Forecast: Up 5.5% Today

Chainlink ($LINK) Crypto Forecast: Up 5.0% Today

Ethereum Name Service ($ENS) Crypto Forecast: Up 5.2% Today

Aave ($AAVE) Crypto Forecast: Up 5.1% Today

Aptos ($APT) Crypto Forecast: Up 5.3% Today

Sui ($SUI) Crypto Forecast: Up 5.0% Today

Edwards Lifesciences Corporation Price History

18.10.2024 - EW Stock was up 3.6%

• Despite facing multiple securities class action lawsuits and allegations of securities law violations, Edwards Lifesciences (EW) saw a strong bullish movement in the market today.
• Investors might be optimistic about the company's ability to navigate through the legal challenges and maintain its market position.
• The bullish trend could also be attributed to positive developments in the company's core business operations or potential market opportunities that investors are anticipating.
• It appears that market sentiment towards Edwards Lifesciences (EW) remains resilient in the face of legal uncertainties, driving the stock price higher.

30.09.2024 - EW Stock was down 4.7%

• Lawsuits and alerts about losses appear to have impacted investor confidence in Edwards Lifesciences Corporation (EW).
• Trading trends show a significant focus on put options, suggesting a bearish sentiment among investors.
• An upcoming deadline for investors who purchased shares during a specific period may have contributed to the selling pressure on EW stock.
• Overall, negative news flow and legal actions surrounding EW likely influenced the bearish market movement observed today.

08.09.2024 - EW Stock was up 6.1%

• The bullish movement in EW could be attributed to investors recognizing the company as a better value option compared to its competitor TFX.
• Positive sentiment surrounding Edwards Lifesciences' products and potential growth prospects might have contributed to the stock's upward trajectory.
• The comparison with TFX could have sparked increased interest in EW, leading to higher demand and a bullish market movement.

28.09.2024 - EW Stock was down 2.5%

• The stock of Edwards Lifesciences Corporation (EW) experienced a strong bearish movement today.
• The market reacted negatively to the series of investor alerts and class action lawsuit announcements against Edwards Lifesciences Corporation.
• The legal actions and fraud alerts likely raised concerns among investors, leading to a sell-off of EW shares.
• The uncertainty surrounding the lawsuits and potential violations of securities laws may have contributed to the bearish sentiment and downward pressure on the stock price.

17.08.2024 - EW Stock was down 2.5%

• Despite bullish options activity, Edwards Lifesciences (EW) experienced a strong bearish movement today.
• The discrepancy between the bullish options activity and the bearish market movement could indicate a divergence in sentiment among investors.
• It's possible that external factors such as broader market trends or specific company news overshadowed the optimistic options activity, leading to the bearish movement in EW's stock.
• Investors should closely monitor any upcoming developments or news that could provide more clarity on the stock's unexpected performance.

05.08.2024 - EW Stock was down 6.1%

• There is a notable options frenzy surrounding Edwards Lifesciences, suggesting that well-funded investors are taking a bearish view on the stock.
• This negativity could be attributed to concerns related to the company's financial performance, potential regulatory challenges, or broader market conditions affecting the healthcare industry.
• Investors are advised to closely monitor these indicators as they could signify a shift in sentiment towards Edwards Lifesciences, potentially resulting in further downward pressure on the stock price.

04.11.2024 - EW Stock was up 5.1%

• Today, the positive outlook outlined at an investor conference contributed to the bullish movement in Edwards Lifesciences' stock. The company is anticipated to experience growth in total sales and therapy segments.
• Despite dealing with investor class action lawsuits and alerts from various law firms, the market appears to be more interested in the company's growth potential and financial prospects.
• Investors are showing optimism towards the potential expansion in TAVR and TMTT sales, potentially overshadowing the legal hurdles currently faced by the company.
• The recent market trend indicates that investors are primarily influenced by Edwards Lifesciences' future growth opportunities rather than its ongoing legal challenges, resulting in an upward momentum in the stock price.

04.11.2024 - EW Stock was up 5.6%

• The bullish movement in EW stock could be attributed to investors gaining confidence in the company's ability to navigate through the legal challenges it is currently facing.
• Despite the negative news surrounding class action lawsuits and investor losses, the stock's bullish movement suggests that investors may believe the company will successfully address these issues and continue to thrive in its industry.
• The upcoming deadlines for filing lawsuits may have created a sense of urgency among investors, leading to increased trading activity and a surge in the stock price.
• It is essential for investors to closely monitor any developments related to the legal proceedings and assess the potential impact on the company's financial performance in the future.

26.06.2024 - EW Stock was down 8.6%

• Edwards Lifesciences shares plunged 31% after being downgraded by J.P. Morgan and Truist due to concerns about heart valve replacement sales growth.
• The stock hit a 52-week low, trading at $60.53, reflecting the negative sentiment surrounding the company.
• Dampened expectations for heart valve replacement sales growth contributed to the stock's sharp decline.
• The overall market sentiment, particularly in the tech sector, remained in the "Fear" zone, with tech stocks faltering and impacting investor confidence in companies like Edwards Lifesciences.

25.06.2024 - EW Stock was down 29.7%

• We observed that Edwards Lifesciences faced challenges in sales performance for the second quarter, coupled with a conservative outlook for the third quarter, prompting a decline in the stock value.
• Analysts revised their projections for EW downwards due to unmet expectations in TAVR (Transcatheter Aortic Valve Replacement) growth, leading to a reduction in the price target.
• The recent acquisitions of JenaValve and Endotronix by Edwards Lifesciences may have influenced investor confidence, contributing to the stock price decrease.
• Following the release of the earnings report showing missed growth targets, negative sentiment towards the company likely drove the considerable decrease in Edwards Lifesciences stock value.

25.06.2024 - EW Stock was down 23.2%

• Edwards Lifesciences (EW) stock experienced a significant 22% decline today.
• The company's earnings report for the second quarter of 2024 revealed mixed results, with adjusted EPS slightly beating estimates but revenue falling short of expectations.
• Investors were particularly disappointed with the lower-than-expected growth in the Transcatheter Aortic Valve Replacement (TAVR) segment, which impacted the overall revenue performance.
• Additionally, market trends and concerns about divestiture challenges might have added to the negative sentiment surrounding Edwards Lifesciences stock, contributing to the bearish movement observed today.

25.06.2024 - EW Stock was down 28.3%

• Edwards Lifesciences (EW) stock witnessed a sharp 22% drop following disappointing revenue figures in the second-quarter earnings.
• While the company exceeded earnings per share estimates, its revenue of $1.63 billion fell short of the $1.65 billion expected by analysts.
• The slower growth in the Transcatheter Mitral and Tricuspid Therapies (TMTT) product group and underperformance in Transcatheter Aortic Valve Replacement (TAVR) were contributing factors to the negative reaction from the market.
• Investors responded unfavorably to the revenue miss, overshadowing the positive earnings beat and robust performance of the TMTT product group.